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 The use of epigenetic modifying drugs such as DNA methyltransferase inhibitors 
(DNMTi) and histone deacetylase inhibitors (HDACi) is becoming more common in the 
treatment of cancer.  Currently, there is a profound interest in determining predictive 
biomarkers for patient response and the efficacy of known and novel drugs.  There are 
likely distinct “epigenetic profiles” defined by the location and abundance of DNA 
methylation patterns and histone modifications.  Here we propose to investigate the 
response of a selected subset of genes to particular DNMTi and HDACi treatments, in 
two human cancer cell lines, colorectal carcinoma HCT-116 and liver adenocarcinoma 
HepG2.  In this study we identified unique epigenetic profiles based on microarray and 
bioinformatics derived epigenetic data that are predictive of the response to epigenetic 
drug treatment.  Microarray studies were used to identify re-activated genes common in 
two different cancer cell types treated with epigenetic drugs.  Bioinformatics data was 
compiled on these genes and correlated against re-expression to construct the genes’ 
“epigenetic profile”.  We then verified the response of the select group of genes in HCT-
116 and HepG2 upon treatment at varying concentrations of epigenetic drugs and 
illustrated that selective reactivation of the target gene.  Additionally, two novel genes 
were introduced and one selectively activated over another. 
 Further research would prove invaluable for the medical and drug development 
communities, as a more extensive model would certainly be of use to determining 
patient response to drug treatment based on their individual epigenetic profile and 
leading to more successful novel drug design.
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CHAPTER I 
CANCER AND EPIGENETICS 
 
 
 Cancer is the second leading cause of death in the United States (Siegel et al., 
2015).  Each year cancer contributes to the death of approximately 8.2 million individuals 
worldwide accounting for 21.7% of deaths due to non-communicable diseases (WHO, 
2014).  The American Cancer Society estimates that almost 600,000 Americans will die 
in 2016 due to cancer while, simultaneously, there will be over 1.6 million new cases of 
cancer reported by the US alone.  These same predictions suggest that roughly an equal 
number of cases will be discovered in both men and women, but females are projected 
to have a higher survival rate.  From 2009 – 2012, incidence rates in women have 
stabilized and decreased by 3.1% in men (Siegel et al., 2016).  While some studies 
suggest that the mortality rates of cancer are decreasing (Ryerson et al., 2016) others 
point out that these statistics are heavily skewed by early detection methods and do not 
necessarily represent realistic changes in survival rates (Cho et al., 2014).  Even with 
our advances in technology and medicine, cancer is still a very real threat. 
 It was initially suspected that human cells would divide infinitely. However, early 
in vitro studies of human cell lines found that there is a finite number of times that a cell 
can replicate; this has become known as the Hayflick limit (Shay & Wright, 2000) .  
Under normal circumstances cells reach this point, somewhere between 40 and 60 
divisions, and become senescent.  Many different cellular mechanisms help to reinforce 
this limited replication.  In cancer, cells manage to bypass the preventative measures 
intended to force a cell into senescence.  This evasion of senescence, is one of the six 
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fundamental traits proposed as the hallmarks of cancer (Hanahan & Weinberg, 2011).  
In addition to enabling replicative immortality, the list of required steps for a cell to 
progress to cancer include: sustaining proliferative signaling, resisting cell death, 
evasion of growth suppressors, activation of invasion and metastasis, and inducing 
angiogenesis (Hanahan & Weinberg, 2011).  Studies have shown that transforming 
growth factor-β inhibits proliferation while deletion of the receptor or perturbations to its 
signaling pathway can result in continuous cellular division (N. Cheng et al., 2012).  Most 
cells that escape the Hayflick limit or manage to divide continually will eventually incur 
enough DNA damage causing the cell to undergo apoptosis.  It is therefore necessary 
for a cancerous cell to develop mutations in apoptotic pathways (Adams & Cory, 2010).  
In order to be able to move away from its original location a cancer cell normally disrupts 
the E-cadherin pathway, which would normally keep it anchored to surrounding cells, 
thereby allowing it to metastasize into foreign areas (Berx & van Roy, 2009).  As a cell 
metastasizes from one location to another, it will continue to grow.  When a cell mass 
reaches sufficient size, it can no longer transport enough nutrients to the centralized 
cells and must begin recruiting new blood vessels.  This aids not only in the ability to 
gather nutrients, but also to obtain oxygen and rid the cells of their metabolic waste 
products (Wicki & Christofori, 2008).  Together, these traits result in a successful cancer 
cell, uninhibited by limitations of normal cells and capable of wreaking havoc on the 
body. 
 Normal cells don’t acquire all of the hallmarks of cancer at a single time.  Rather, 
a normal cell will move from its typical state to that of aggressive or invasive cancer 
progressively, sometimes not even successfully completing the transition.  Between the 
normal cell and the far end of the cancer spectrum exist multiple stages that are defined 
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by the amount of cancerous characteristics that the cell possesses.  Cancer progression 
and the appearance of the hallmarks of cancer involve changes in multiple genes that 
can broadly be classified as oncogenes and tumor suppressors.  The oncogenes are 
normal cellular genes that are involved in cell proliferation.  These include growth 
receptors (Yu et al., 2014), signaling pathway proteins (Liang et al., 2016), and 
transcription factors (Jacques et al., 2016).  Oncogenes are gain of function mutations 
such that the protein is generally in an active state or overexpressed (D. Jiang et al., 
2015).  The Ras protein and its pathway components are classic examples of proto-
oncogenes, known to be mutated to oncogenes.  In contrast, tumor suppressors are 
genes that normally function in growth control and cell cycle checkpoint and are loss of 
function mutations in cancer cells (Peyser et al., 2015).  P53, which responds to DNA 
damage, stops the cell cycle for either DNA repair or else initiates apoptosis, is a classic 
example of a tumor suppressor (Ferraiuolo etal., 2016).  Other genes mutated during 
cancer progression are outside these two general categories and include DNA repair 
genes and genes involved in genomic stability (Chae et al., 2016; Pérez-alea et al., 
2016). 
 The mutations in the oncogenes and tumor suppressors result from a 
combination of genetic mutations or epigenetic alterations, referred to as epimutations 
(Coppedè et al., 2014).  Tumor suppressor genes, in particular, tend to undergo 
epimutations in cancer (Shakeri et al., 2016).  The most extensively studied epimutation 
is DNA methylation, but others such as histone acetylation and methylation are also well 
characterized.  Many of the genes that are misregulated in cancer are the joint effect of 
DNA methylation and histone modifications (Blackledge et al., 2010; Rose & Klose, 
2014; Rothbart & Strahl, 2014). 
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 DNA methylation normally occurs in CpG dinucleotide rich regions termed CpG 
islands (CGI).  These islands possess a CG content of at least 50% and are, at minimum 
200bp in length (N. Jiang et al., 2014); they are usually found overlapping the promoter 
region of a significant proportion of genes (60 – 70%), of which most remain 
unmethylated in non-tumorigenic cells (Lao & Grady, 2011).  Aberrant DNA methylation 
causing inactivation of tumor suppressor genes is frequently seen in colorectal, 
hepatocellular, prostate, breast, lung, and renal cancer (Weisenberger, 2014).  DNA 
methylation is the conversion of cytosine to 5-methylcytosine through the addition of a 
methyl group to the 5’ position of the pyrimidine ring of cytosine.  This covalent 
modification is catalyzed by DNA methyltransferase (DNMT), of which there are multiple 
forms; DNMT -3a / -3b which mediate de novo methylation, while DNMT1 maintains pre-
existing methylation patterns with the help of DNMT3b (Esteller, 2002; Gravina et al., 
2010; Rhee et al., 2002).  Methylation of DNA inhibits numerous proteins such as 
transcription factors from binding, and can aid in the formation of a heterochromatic 
state, thereby reducing gene transcription (Herman & Baylin, 2003; Nan et al., 1998; 
Thomson et al., 2010).  In general DNA methylation is associated with a reduction in the 
transcription of the gene body in which it resides. 
 Methylation pattern maintenance occurs during DNA replication by copying the 
methylation pattern present on the parent strand, signifying that it is a reversible 
process.  Recent studies have shown that DNA methylation relies on particular histone 
modifications and in turn, histone modifications alter presence and density of DNA 
methylation (Blackledge et al., 2010; Tamaru & Selker, 2001; Wozniak & Strahl, 2014). 
 Histone modifications affect chromatin structure and therefore also effect 
transcription.  Numerous histone modifications occur; of these, the most frequently 
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investigated are histone methylation and histone acetylation.  The histone modification, 
Histone 3 lysine 27 acetylation, is an example of a histone modification that is 
associated with active promoters (Cai et al., 2015).  Acetylated histones receive their 
moieties through histone acetyltransferases (HATs) and cofactor acetyl-CoA.  Acetyl 
groups can be removed from the ε-amino groups of lysine residues by histone 
deacetylases (HDACs), causing a more compact chromatin state and interfering with 
transcription (Heerboth et al., 2014; B. Shi, 2013).  Most histone methylation occurs 
similar to histone acetylation as lysine methyltransferases (KMTs) add a methyl group to 
the histone tail from S-adenosylmethionine (Drake et al., 2014).  Two commonly studied 
KMTs are DOT1L (Angelica & Fong, 2008) and EZH2 (Agarwal et al., 2016).  In many 
cases histone methylation is viewed as a repressive mark (Zhao et al., 2016) while 
others, such as mono and tri methylation of histone 3 lysine 4 are considered active 
marks (Cai et al., 2016; Rawat et al., 2016).  Histone methylation is dynamic, being 
added and removed from histones by multiple enzymes.  There are over 20 lysine 
demethylases (KDMs) that are capable of removing the methyl group from particular 
histone residues (Zahnow et al., 2016). 
 The effects of DNMTs on DNA methylation and HDACs on histone deacetylation 
can be interrupted or reversed upon cellular division through the use of DNA 
methyltransferase inhibitors (DNMTi) and histone deacetylase inhibitors (HDACi) 
(Heerboth et al., 2014; Lyko & Brown, 2005; Treppendahl, et al., 2014).  DNMTi are a 
class of drugs that either directly block DNA methyltransferase activity by blocking the 
active site of DNMT1 or by acting as a target themselves, and locking hold to DNMT1, 
depleting all that is available.  Such is the case with 5-azacytidine (5-aza).  By either 
means, inactivation or depletion, DNMTi effectively reduces the amount of methylation 
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with each successive division.  The decrease in methylated DNA results in an increase 
in previously silenced genes.  There is conflicting evidence as to whether or not DNMTi 
have much of an effect on non-cancerous cells.  Some studies show that DNMTi caused 
an increased incidence of tumors in murine models (though these doses were higher 
than used in clinical settings), whereas more recent studies suggest that due to a lower 
rate of metabolism and division, normal cells do not experience the same effect as seen 
in treated malignant cells (J. C. et al. Cheng, 2004; Stresemann & Lyko, 2008).  
Interestingly, some studies have suggested that treatment with DNMTi not only results in 
demethylation of hypermethylated regions, but can also restore methylation to 
hypomethylated regions as well (Heller et al., 2008).  Currently, 5-Azacytidine is used in 
the treatment of myelodysplastic syndromes such as leukemia (Raj & Mufti, 2006), .  
Others have proposed the use of DNA methylation biomarkers for the use in the 
detection of colorectal cancers with highly methylated CpG islands (Laird & PE Lange, 
2013).  The effectiveness of such a method would suggest that these tumors would be 
sensitive to treatment with 5-Aza as some studies have already illustrated (Zouridis, 
2012).  Further investigations have performed genome-wide methylation screening 
before and after 5-Aza treatment in order to discover potential methylation markers to 
better determine which patients may benefit more from treatment with the DNMTi 
(Decock et al., 2012), while yet others have searched for these types of markers based 
on single tumor suppressor genes such as RECK (G. Shi  etal., 2016). 
 HDACi are a much more complex group of enzymes than DNMTi, that restore 
the histone acetylation balance.  These agents have been of extreme interest due to the 
fact that they cause the acetylation of both histones and non-histone proteins, such as 
p53 (Treppendahl et al., 2014).  Though histone deacetylation is common even among 
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non-cancer cells, HDACi only affect 2-10% of expressed genes (Heerboth et al., 2014).  
Some HDACi such as Vorinostat are commonly used in the clinical setting due to their 
intrinsic nature to prevent deacetylation and their ability to resensitize radiation and 
chemoresistant cells (Coppedè et al., 2014; Heerboth et al., 2014; Lyko & Brown, 2005; 
B. Shi, 2013; Treppendahl et al., 2014). 
 New treatment strategies for cancers are now including the application of 
epigenetic drugs including DNA de-methylating agents, histone acetyltransferase 
inhibitors, and histone methyltransferase inhibitors (Khanahmadi et al., 2015; Miranda et 
al., 2009; Takeshima et al., 2014; Vasilatos et al., 2013).  Just as with the gene 
mutations, each individual tumor is likely to have a particular “epigenetic profile” 
associated with genes that show epimutations.  Thus, a patient’s response to an 
epigenetic drug will depend not only on the genes that are silenced by epigenetic 
mutations, but also on the specific epigenetic profile of those genes.  As there has been 
a move towards genotyping tumors (Kumarakulasinghe et al., 2015), it may prove highly 
informative to determine the epigenetic profiles for specific silenced genes in the tumor 
types, as these profiles may prove predictive for drug therapy.  This epigenetic profile 
would consist of the DNA methylation and histone modifications up and downstream of 
the gene’s start of transcription, and could be obtained using a variety of high throughput 
approaches currently available. 
 The main goal of this study was to determine if currently available epigenetic 
bioinformatics data are predictive for gene activation by the DNA methyltransferase 
inhibitor 5-Azacytidine (5-Aza).  In a more limited study, we also tested the effects of 
histone deacetylase inhibitor SAHA.  The major hypothesis is that activation of a gene by 
5-Aza will have sites of DNA methylation in sequences surrounding its start of 
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transcription, as determined by the bioinformatics databases and, gene activation by the 
inhibitor SAHA will be associated with a lack of histone acetylation marks.  To 
accomplish our goals the following specific aims were completed: 
1. Examined bioinformatics data to identify re-activated genes common in two different 
cancer cell types, HCT-116 and HepG2, treated with the DNA methyltransferase 
inhibitor, 5-Azacytidine and correlated these changes to the “epigenetic profiles” of the 
genes derived from current bioinformatics data. (Chapter II) 
2. Determined the selective reactivation of a select group of the common genes in HCT-
116 and HepG2 with 5-Aza and correlated these changes with their epigenetic profiles. 
(Chapter III) 
3. Predicted the reactivation of a novel gene, WNT5A promoters A and B, after treatment 
with 5-Aza and SAHA, based on epigenetic profiles. (Chapter IV) 
 The epigenetic profiles were defined within a 1000bp region, centered at the 
transcription start site, with 500bp upstream and 500bp downstream.  Within these 
regions a profile was defined as the number and locations of methylation sites and the 
type of histone modifications.  ENCODE (the Encyclopedia of DNA Elements) was the 
main source of epigenetic information.  This database allows access to epigenetic data 
(DNA methylation and histone modifications) for many different cell lines, and is 
searchable to the gene and then sequence levels.  The data have been gathered by 
institutes worldwide and is verified multiple times before release to the public. 
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CHAPTER II 
CONSTRUCTION OF EPIGENETIC PROFILES 
 
 
 The goal of this study was to determine if it is possible to predict the re-
expression of genes upon treatment with the DNA methyltransferase inhibitor 5-Aza, 
based on “epigenetic profiles” derived from bioinformatics databases.  To meet that goal 
it was first necessary to select microarray studies that had used 5-Aza and then define 
the epigenetic profiles of a subset of the genes, followed by statistical analysis of these 
profiles to build a model of gene reactivation after 5-Aza treatment.  
 ArrayExpress (www.ebi.ac.uk/arrayexpress) and Gene Expression Omnibus, GEO 
(http://www.ncbi.nlm.nih.gov/geo/), databases serve as easily accessible sources for 
high-throughput experimental data including microarray based DNA, mRNA, and 
proteomic experiments (Barrett et al., 2013; Kolesnikov et al., 2015).  The three main 
goals of GEO include data organization, easy submission of data while simultaneously 
ensuring quality, and user friendly query and analysis.  Submissions to GEO can take 
two forms, either a GEO Series record, which is the original submission file, or GEO 
Datasets, which are a collection of biologically relevant and statistically comparable GEO 
Series files which have been collected and analyzed by GEO.  Only GEO Datasets are 
available for further analysis using the database’s advanced tools for gene expression 
profiles and clustering.  This database is easily queried and provides quick search 
results based on selection of key words such as a specific cell line and treatment type 
(Edgar et al., 2002).  While GEO uses only data submitted to it directly, ArrayExpress 
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uses both direct submissions and data from GEO, therefore containing a greater 
likelihood of containing a combination of a specific cell line and treatment. With the use 
of statistical programs such as R, it is possible to cross analyze and organize the data 
from two or more given microarrays, resulting in any shared information between the 
two.  While this reorganization is straightforward it does not result in useable information 
in regards to fold-change.  In order to ensure that the levels of fold-change are 
comparable to one another and that their fold change is due to more than chance alone, 
it is necessary to apply a technique such as the significance analysis of microarray 
(SAM) procedure (Tusher et al., 2001).  The SAM statistic is a variant of the t-statistic 
that includes a constant inflation factor in the denominator to overcome large statistics 
attributable to small fold changes and extremely low error estimates that arise when 
performing thousands of tests on cohorts of small sample size.  SAM also uses a 
permutation strategy to produce an empirical false discovery rate (FDR), and thus is a 
model-free approach.  This FDR is a score assigned by the model, where higher scores 
suggest that the fold-change is due more to chance than experimental conditions. 
 In 2003, the National Human Genome Research Institute, launched an initiative 
to form an international collaboration of various research groups that would work on 
building a collection and annotation of the functional elements of the human genome 
called the Encyclopedia of DNA Elements, or ENCODE.  A series of multiple levels of 
data production and verification ensure high quality data (Myers et al., 2011).  Individual 
experiments are performed at multiple institutions across the world and sent to the data 
center where it is validated, stored, and made accessible to the public.  Each experiment 
searches for a single functional element, including DNA methylation and histone 
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modifications.  These experiments are represented as tracks in the public database and 
are specific to cell type. 
 It is possible to visualize the ENCODE cell specific tracks at any given locus by 
either typing the various gene ID/symbol or chromosome number and region.  There are 
multiple DNA methylation tracks, comprised of the 450K microarray track and reduced 
representation bisulfite sequencing (RRBS) track.  Most cell lines have multiple 
replicates which are experimental repeats for the purposes of validation and accuracy.  
The 450K microarray is a wonderful tool to use when investigating a large number of 
samples due to speed and overall coverage.  Due to technical limitations of designing 
450K microarrays, they are only able to assay about 1.8% of CpGs and typical only 
cover those found in genes or CpG islands (Butcher & Beck, 2015).  Reduced 
representation bisulfite sequencing has the ability to cover a larger percentage of the 
CpGs, being a sequencing method rather than a microarray.  With a sufficient number of 
reads for both the 450K microarray and RRBS, the two tend to agree at extreme values, 
very high levels of methylation, and very low levels.  However, in the upper and lower 
20% values, the two are inconsistent with one another (Pan et al., 2012).  It is because 
of these reasons that it can be beneficial to use both the 450K and RRBS tracks when 
investigating DNA methylation in ENCODE. 
 Additional epigenetic tracks on ENCODE include histone modifications.  Some 
cell lines have been investigated in more depth than others and therefore have a larger 
selection of histone tracks available.  Three of the available tracks for many cell lines are 
for the histone marks: H3K4me1, H3K4me3, and H3K27ac.  All three of these marks are 
associated with active gene promoters (Aday et al., 2011; Creyghton et al., 2010; 
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Pekowska et al., 2011).  By considering this information in addition to DNA methylation, 
it is possible to get a clearer view of the epigenetic profile of the locus. 
 Analyzing regions spanning 10,000 to 1,000bp around the TSS is fairly common 
when looking for epigenetic marks (Ucar et al., 2011; Wang et al., 2009).  In a recent 
study it was found that a 1000bp window was large enough to identify correlations 
between histone modifications and DNA methylation (Linghu et al., 2013).  As a gene’s 
promoter is within only a few hundred base pairs upstream of the TSS, attempts should 
be to try and capture a region not directly affected by the typical adenine and thymine 
rich nature of the promoter to better investigate the DNA methylation without bias.  By 
using a 1000bp window centered at the TSS, this type of situation can be avoided in 
many cases.  Further breaking the 1000bp region into 50bp bins will allow for a more 
thorough inquiry into specific regions.  When this window is used in conjunction with the 
epigenetic track from ENCODE it is possible to construct an epigenetic profile of the TSS 
of each gene under study. 
 By constructing epigenetic profiles of genes we hypothesize that it will be 
possible to predict their re-expression upon treatment with the DNA methyltransferase 
inhibitor, 5-Azacytidine, using a model generated through analysis of 5-Aza treated 
microarray data.
Materials and Methods 
5-Azacytidine treated microarrays for HCT-116 and HepG2 
 Microarrays in the ArrayExpress database were searched using the conditions of 
cell line and 5-Aza treatment.  Two microarrays were obtained, HCT-116 (Data available 
in ArrayExpress database (Li et al., 2014), under accession number E-GEOD-57341) 
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and HepG2 (Data available in ArrayExpress database (Dannenberg & Edenberg, 2006), 
under accession number E-GEOD-5230).  The microarray for HCT-116 treated cells with 
0.5µM 5-Aza for 72 hours, whereas the HepG2 microarray treated with 2.5µM for 96 
hours. 
Determination of microarray shared genes and fold change 
 The Significance Analysis of Microarray (SAM) procedure was used to test for 
differential expression and estimate fold change between experimental conditions.  SAM 
was implemented in R version 3.1 using the package ‘samr’.  
Construction of “epigenetic profiles” 
 “Epigenetic profiles,” defined as 1000bp regions centered at the transcription 
start site and consisting of DNA methylation and histone mark scores and abundance, 
were constructed in two different manners; initially by hand for a group of 32 selected 
genes and later by using a mixture of GALAXY, ENCODE, and Excel.  
 Hand construction of the epigenetic profiles was performed using ENCODE to 
explore the methylation and histone modification tracks of 32 genes selected from the 
microarray studies based on differential re-expression of any given gene between cell 
lines.  The genes that were selected illustrated both extremes (low fold-change and high 
fold-change) and others that fell in between in an attempt to prevent any form of bias.  
Each track was examined in windows of 50 base pairs each starting at the transcription 
start site and extending 500 base pairs in each direction.  Methylation data was collected 
for HCT-116 and HepG2 by analyzing two RRBS tracks for HCT-116 and two RRBS 
tracks for HepG2; these numbers were averaged together for the tracks of each cell line 
and recorded.  Additionally, two 450K tracks for HCT-116 and one 450K track for HepG2 
were collected and recorded.  When more than one track was available the scores for 
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450K were averaged in the same manner as RRBS.  When analyzing histone 
modifications, we selected those which were shared between the two cell lines:  
H3K4me1, H3K4me3, and H3K27ac tracks (all which are associated with active 
promoters).  Two tracks were used for analysis of HCT-116 H3K4me3 (Peaks 1 & 2), 
while 3 were used to analyze the same modification in HepG2 (Peaks 1, 2, & 
ENCODE/Broad).  In the event that a peak was detected that stretched outside of the 50 
base pair window, the score was carried over into all 50bp windows that it was located 
in, so long as it accounted for at least 25bp of that window.  No scores were given for 
anything further than 500bp up/downstream.  If more than one peak was present in a 
single track set, the two scores were averaged if they were the same length, so long as 
both accounted for at least 25bp of the given window and they were the same length, if 
not the shorter band’s score was taken since it is considered more accurate by 
ENCODEs standards.  For all histone tracks and the 450K track, numbers ranged from 0 
– 1000; the RRBS track ranged from 0 – 100.  These numbers indicated the RRBS track 
indicated the percentage of reads that showed methylation at a given CpG, whereas the 
450K track scored based on the microarrays beta values, multiplied by 1000.  Histone 
tracks were scored based on the signal value, indicating the average enrichment for the 
region.  When available, multiple tracks of a given epigenetic mark are used as a form of 
biological replicates. 
 Computed construction of the epigenetic profiles was performed using a 
combination of GALAXY, ENCODE, and Excel on any genes in the microarrays where 
either cell line was upregulated after treatment with 5-Aza.  Using the gene symbol for 
each gene, information was pulled on GALAXY from ENCODE containing the gene ID, 
chromosome number, transcription start site, and strandedness.  This information was 
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imported into Excel and cross referenced to expression for each cell line.  The compiled 
information was then uploaded into GALAXY and flanking regions were obtained for 
50bp in a single direction until 500bp regions upstream and downstream were accounted 
for.  Hg19 Tracks for DNA methylation and histone modifications were imported from 
ENCODE into GALAXY.  The tracks used in the computed bioinformatics were the same 
as those that were used in the hand construction with the exception that no RRBS tracks 
were used due to importing issues.  All rules followed previously for scoring were 
maintained.  The 50bp flanking regions for each gene were crossed with the track 
information from ENCODE in GALAXY.  The results were imported into Excel for easy 
data sorting and a single master file containing the information of each gene, location, 
and epigenetic mark.  
Predicted Protein Interactions 
 String version 10 was used to determine protein-protein interactions of 32 
selected genes using summary network, actions display.  (www.string-db.org) 
Principal Component Analysis 
 Interactions between 10 components of the hand constructed method and 
separately, nine in the computed method were investigated through PCA.  PCA  used R, 
statistical analysis software to determine where the largest amount of variation in the 
dataset existed while also reducing dimensionality.  Data for the analysis was pulled 
from the 32 selected genes and standardized so that standard deviation was 1.  PCA 
was executed to analyze the relationships between these components. 
Elastic Net Regression 
 Each figure (scores, location, and number) was correlated with fold change for 
HelpG2 and HCT116 using spearman and pearson statistical tests prior to Elastic Net 
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Regression, a penalized likelihood regression method that selects and estimates 
regression coefficients based on the correlation structure of the predictors and performs 
well when predictors are highly correlated.  If a correlation of >0.1 or <-0.1 was found 
then Elastic Net regression was run using R version 3.1 with the package, ‘glmnet 2.0-5’.
Results 
 We hypothesized that “epigenetic profiles” derived from scores of epigenetic 
marks obtained from bioinformatics databases can be used to generate a model that 
predict changes in expression due to 5-Azacytidine (5-Aza).  
 To test this hypothesis, we used gene expression data from microarray studies of 
5-Aza treated cells and combine those results with epigenetic marks derived from 
bioinformatics databases, in particular ENCODE. We searched the online database of 
microarray studies on ArrayExpress.  Our search was refined by looking for the cell 
lines, HCT-116 and HepG2.  These cell lines were selected due to the large number of 
tracks available on ENCODE for these two cell lines.  Two microarrays with similar 
concentrations and durations were found, E-GEOD-57341 and E-GEOD-5230.  The 
microarray, E-GEOD-57341, was of HCT-116 cells that had been treated with 0.5µM 5-
Aza for three days, whereas E-GEOD-5230 represented HepG2 cells treated with 2.5µM 
5-Aza for 4 days. 
 The microarrays were cross-analyzed to determine which genes were shared 
between both, along with the relative fold-change of the genes after treatment.  In all, 
28,247 probes were found to be shared between the two microarrays.  Of those probes 
there were 17,381 unique genes and 734 loci or genes that did not match a known gene 
name or kgAlias in the ENCODE database. 
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 To generate the hand constructed epigenetic profile (Fig. 1), we selected 32 
genes with varying levels of fold-change from a list of the microarrays in which both cell 
lines showed upregulation for a given gene.  These genes were then analyzed for 
interaction on the protein-DNA and protein-protein levels, using String ver. 10, finding 
that only two interacted (Fig. 4).  This interaction was on a protein-protein level and upon 
review it was determined that the effect of 5-Aza on the 32 genes did not involve 
interaction among these proteins.  We did not perform this same analysis on the entirety 
of both microarrays due to limitations of the online database.  All genes were then 
analyzed for DNA methylation and histone modifications using ENCODE hg19, using as 
many tracks as were available and shared between both HCT-116 and HepG2 cell lines.  
The tracks found in common included reduced representation bisulfite sequencing 
(RRBS) and 450K for methylation and H3K4me1, H3K4me3, and H3K27ac to 
investigate histone modifications.  These represent active histone marks; no repressive 
histone mark tracks were available.  Any replicate tracks available for the epigenetic 
modifications were included in the study.  Epigenetic profiles were constructed by 
analyzing 500bp upstream and 500bp downstream of the TSS, each being broken apart 
into 50bp windows, and recording the value and location for each epigenetic mark.  
Upon completion of the hand constructed epigenetic profiles, PCA and elastic net 
regression statistical tests were performed.  An example of tracks for the highly activated 
gene MYL9 and PPDPF, found in both HepG2 and HCT-116 is shown in Fig. 3. 
 Principal component analysis of the hand constructed epigenetic profiles for the 
selected 32 genes (Table 1) illustrate the correlations in our dataset.  Using 
approximately a 0.4 correlation cut-off value, principal component 1 displays a positive 
correlation between the total number of histone modifications and H3k4me1/me3 and 
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H3K27ac histone marks, accounting for the largest amount of variation in the dataset.  
Principal component 2 shows that the second largest variation is seen in genes 
possessing a higher proportion of methylated CpGs than non-methylated, scored by 
RRBS, located slightly upstream of the TSS.  The third principal component finds that 
fold-change is positively correlated with high values of methylation scores, whereas 
these two features hold a negative correlation with H3K27ac.  In principal component 4 a 
negative correlation in higher levels of methylation was found between the RRBS track 
and 450K methylation scores, located further downstream.  The remaining principal 
components possessed a value of less than 1 for the square root of eigenvalues, 
indicating that they could be due simply to chance.  For that reason, they were not 
considered during analysis or generation of a model.  As a whole this analysis found that 
most variation is seen in histone mark scores and abundance, whereas methylation 
found through the RRBS track is located slightly upstream of the TSS and further 
downstream.  Additionally, PCA revealed that expression (as indicated by fold-change) 
seems to be most closely correlated with higher levels of methylation scores and a lack 
of H3K27ac. 
 Following PCA, Spearman and Pearson statistical tests were run on the hand 
constructed epigenetic profiles to verify a correlation of >0.1 or <-0.1 between fold 
change and features.  These features consisted of any combination of either histone 
modifications or DNA methylation.  Verifying that there was a correlation, elastic net 
regression of the hand constructed profiles was performed in R.  The data, while 
nonsignificant, showed a trend at approximately 15 features.  These features consisted 
of any combination of methylation or histone modifications.  This indicates types of 
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methylation scores (RRBS or 450K), number of methylated CpGs, and individual histone 
scores. 
 To increase the power to detect significant features, the analysis of the 
microarray data was extended to the entire dataset.  The entire list of 17,381 gene 
symbols previously filtered for the generation of the manual list genes was used to 
construct the computed epigenetic profiles (Fig. 2).  The gene ID’s for these genes were 
pulled from ENCODE using GALAXY.  This resulted in a list of 43,461 transcripts of the 
genes.  The list was imported into Excel and cross referenced with gene symbol, TSS, 
strandedness, and fold-change for both cell lines.  The number of transcripts was 
reduced to 11,480 by filtering out duplications and those for which GALAXY and 
ENCODE did not pull sufficient data.  The new list was imported back into GALAXY in 
order to analyze 50bp windows of DNA methylation and histone modification that had 
been imported from ENCODE.  All tracks used in the process were identical to those that 
were used in the hand construction, with the exception of that we did not include the 
RRBS tracks as we were unable to obtain the desired information from them.  The 
resulting files were transferred to Excel and arranged into a single master file. 
 We ran principal component analysis on the computed epigenetic profile list of 
the 11,480 transcripts and their features (Table 2).  During our analysis we applied a 
threshold of approximately 0.40 for the cut-off value when determining correlation.  We 
found that PC1 is a measure of the total number of modified histones and that it strongly 
correlates in a positive manner with the scores of H3K4me1 and H3K27ac.  Principal 
component 2 shows a positive correlation of 450K scores and assayed CpGs, located 
very near the TSS.  PC3 was primarily a measurement of fold-change and correlated 
positively with an increase in methylation downstream of the transcription start site.  
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From this point correlations become biologically irrelevant as they possess square root 
eigenvalues that indicate that the correlations are likely due to chance alone. 
 Spearman and Pearson statistical tests were run on the computed epigenetic 
profiles.  Both tests resulted in a lack of correlation of >0.1 or <-0.1 between expression 
and features.  We then attempted to eliminate everything except the extreme values and 
found no correlation.  In another attempt to find a correlation, we meaned and summed 
the entire region, still finding none, therefore, elastic net regression analysis was not 
performed. 
 The results of the computed epigenetic profile’s principal component analysis are 
likely found to have little correlation due to the fact that it included multiple transcripts of 
each gene symbol as it was not feasible to identify which transcript for each was probed 
by the microarrays for so many thousands of genes.  This differs from the hand 
constructed profile where it was easier to identify the transcript used, and where many of 
them had a single isoform.  Additionally, the fact that the RRBS track was not able to be 
included in the computed epigenetic profiles likely contributed to the lack of correlation 
and significance.
Discussion 
 We had hoped to obtain microarray data from ArrayExpress for HCT-116 and 
HepG2 with treatment conditions that we more closely matched one another.  This was 
not possible.  This means that the data may be skewed toward a higher level of relative 
fold-change in HepG2 for any given gene or transcript.  This is likely due to both the 
concentration of 5-Aza, which was 5 times more in HepG2, and the additional 24 hours 
of treatment compared to HCT-116.  While this difference may have shifted the data 
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slightly, it still allowed us to investigate the features present in genes that were 
reactivated.  For future studies, it would be beneficial to perform a microarray experiment 
prior to bioinformatics analysis in order to have consistency between treatments. 
 In our study we performed both a manual hand construction of the epigenetic 
profile and a computed epigenetic profile.  Of these two, the computed epigenetic profile 
was able to collect a far greater amount of data in less time with less chance of 
recording the scores improperly, but also lost a large number of genes.  These genes 
were lost due to difficulties in cross platform analysis.  Using a custom microarray with 
clearly defined genes and specific transcripts, or alternatively, RNA-seq, could help to 
prevent the loss of information.  Furthermore, GALAXY seemed to have difficulties 
pulling the pertinent information from the RRBS track.  It may be possible in future 
studies to create a custom track of the RRBS reads, refining the information which it 
provides in order to obtain what is needed. 
 It appears that the hand construction of the epigenetic profiles was better 
because of the ability to record scores such as those of the RRBS track.  Furthermore, 
we were able to select genes that we saw did not affect the transcription of one another, 
by running a protein-DNA and protein-protein interaction analysis.  Using the manual 
method also allowed the opportunity to investigate the specific isoform that was 
analyzed through the microarrays and used a single transcript for each gene symbol as 
compared to the computed method, in which many cases used three or more transcripts 
per gene symbol.  The issue with multiple transcripts per gene is that it creates multiple 
epigenetic profiles which differ in methylation and histone location and scores, and 
creating an inaccurate representation of correlations to fold-change. 
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 PCA analysis of the hand constructed epigenetic profiles of the 32 selected 
genes and the computed epigenetic profiles both illustrated that the component with the 
largest variation was that of the total number of histones, meaning that the genes 
differed greatly in both their overall histones and which histone marks made these 
scores.  Differences between the microarrays are likely due to RRBS scores not being 
included in the computed epigenetic profile PCA because of lack of availability.  We 
suspect that the lack of this track greatly impacted the analysis.  One of the first and 
most direct ways that lack of RRBS track score affected the data was by reducing the 
number of assayed CpGs.  This is due to the fact that RRBS tends to more successfully 
analyze CpGs near the TSS.  Indirectly, it can be seen that in the manually constructed 
principal component analysis, RRBS forms multiple correlations with histone marks.  
More importantly RRBS has a strong positive correlation with fold change, seen in PC3. 
 The PCA results showed variation in the level of methylation just prior to the 
transcription start site; this makes sense as it is commonly seen in genes with lower 
levels of expression.  Previous studies have found that methylation in the promoter 
region can affect transcription factor binding sites thereby reducing gene transcription 
(Medvedeva et al., 2014); this likely accounts for a portion of the genes that were 
expressed at lower levels prior to treatment with 5-Aza.  Other studies have found that 
the 1000bp window that we investigated contained as little as 1-2% to as much as 10%-
13% CpG content (Couldrey et al., 2014); providing a varying density of CpGs with the 
potential of methylation, contributing to further variability that was picked up by the PCA 
analysis.  The fact that H3K27ac was found to be negatively correlated with DNA 
methylation has been studied before find that tissue specific enhancer regions (such as 
those marked with H3K27ac) are typically unmethylated (Blattler et al., 2014; J. Xu et al., 
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2009).  This is likely to ensure expression of the particular gene.  The correlation seen in 
the hand constructed PCA between fold-change and DNA methylation would be 
expected because of the activity that 5-Aza possesses.  By preventing activity of 
DNMT1, 5-Aza prevents DNA methylation from being replicated after cell division.  This 
reduction in DNA methylation leads to higher levels of gene transcription which we 
calculated as fold-change. 
 The elastic net regression of the manually generated epigenetic profiles did not 
contain enough samples in order to possess any statistical significance, however, a 
trend was discernable.  This trend can be seen as the dip in P-value around 15 features 
(Fig. 5).  These features represent any combination of epigenetic marks whether they be 
DNA methylation, histone modifications, or both in addition to their numbers.  It stands to 
reason that there must be DNA methylation present in order for any DNA 
methyltransferase inhibitor to elicit an effect.  Moreover, extremely high levels of DNA 
methylation within a particular gene would likely reduce the efficacy of the drug.  The 
histone marks, which we analyzed are all considered activating marks are found, 
primarily near transcription start sites.  It is therefore likely that these 15 features 
consisted of DNA methylation and sparse activating histone marks located just upstream 
of the TSS and stretching midway downstream.  An example of this is MYL9 and PPDPF 
(Fig. 3).  MYL9 possessed a relative fold-change of 28.59 in HepG2 and only 1.13 in 
HCT-116.  HepG2 follows the trend found in the elastic net regression with only 19 sites 
of methylation and 3 histone marks.  In HCT-116 it has no methylation and only two 
histone marks.  The gene PPDPF had a fold-change of 1.75 in HepG2 and 1.11 in HCT-
116.  PPDPF had a total of 35 features in HepG2 while it contained only two in HCT-116. 
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 Taking similarities and differences into account from both principal component 
analyses along with the trend seen in the elastic net regression, we were able to 
formulate a general model that represents how responsive a gene is to treatment with 
the DNA methyltransferase inhibitor 5-Azacytidine.  The gene must possess moderate 
levels (10-20 sites) of DNA methylation between 250bp upstream and 250bp 
downstream the start of transcription.  Greater distance than those proposed will reduce 
efficacy of the drug.  The methylated sites should be spread out throughout the region 
rather than clustered, for the most robust effect.   It must also contain one to two 
activating histone marks, preferably either H3K4me3. 
 Our methodology differs from that of others in several ways, namely, we used 
bioinformatics means to obtain both the expression profiles after drug treatment and 
then focused on the promoter regions of the genes that were upregulated.  Other studies 
have selected groups of tumor suppressors to focus on, analyzing only their DNA 
methylation, not histone modifications and used little to no bioinformatics data (Follo et 
al., 2009; Voso et al., 2011). One study like this selected 32 promoter-associated CpG 
islands, finding them to possess a wide range of methylation in NCI-60 cell lines and 
using that information to predict drug response (Shen et al., 2007), while another was 
able to use DNA methylation profiles of differentially methylated regions of patients to 
predict response to a DNMTi, decitabine (Meldi et al., 2015).  
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Figure 1. Hand Collected Flow Chart.  Flowchart detailing the generation of the epigenetic profiles and 
statistical analysis for the hand selected genes from the HCT-116 and HepG2 5-Aza microarrays.	
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Figure 2. Computed Bioinformatics Data Flow Chart.  Flowchart detailing the generation of the 
epigenetic profiles and statistical analysis for the HepG2 and HCT-116 microarrays.  
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Figure 3. ENCODE Snapshot of MYL9 and PPDPF.  Snapshot of ENCODE showing 500bp flanking 
regions of the TSS of MYL9 (top) and PPDPF (bottom) methylation and histone modifications.  DNA 
methylation in RRBS tracks is shown in red (100% methylated), yellow (50% methylated), or green (0% 
methylated).  Representation of DNA methylation as found via 450K array is shown in either orange 
(methylated), purple (partially methylated), or blue (un methylated).  Histone modification tracks are 
represented by dark bars with increased saturation that correlates with relative enrichment of the specified 
modification in that region.  The red bar in the center is helps to identify location, with the center being at the 
transcription start site and a 250bp region blocked off on each side (where then thin red line ends); these 
regions are divided in half representing (2) 125bp regions.  
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Table 1. PCA of Hand Collected Data.  Rotation scores of Principal Component Analysis of the hand 
collected data.  Each PC column represents a single component.  The columns ‘Fold-Change’ through ‘Total 
Number of Histone Mods’ illustrate the degree to which that feature is correlated with the others within the 
principal component.  The last column of each principal component gives the square root of the eigenvalue, 
all values greater than one are considered due to more than chance alone.  Blue cells highlight notable 
correlations within each principal component.  
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Table 2. PCA of Computed Data.  Rotation scores of Principal Component Analysis of the computed 
bioinformatics data.  Each PC column represents a single component.  The columns ‘Fold-Change’ through 
‘Total Number of Histone Mods’ illustrate the degree to which that feature is correlated with the others within 
the principal component.  The last column of each principal component gives the square root of the 
eigenvalue, all values greater than one are considered due to more than chance alone.  Blue cells highlight 
notable correlations within each principal component 
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Figure 4. Protein Interactions.  Analysis of protein interactions for the 32 selected proteins via String ver. 
10.  Proteins are spread for the purposes of visualization.  
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Figure 5. Elastic Net Regression Analysis of Hand Collected Data.  Elastic Net Regression Analysis of 
hand collected 32 genes from the HepG2 and HCT-116 microarrays and bioinformatics analysis.  Shown in 
blue is the smoothed curve of the data.  The gray shaded region illustrates the 99% confidence interval.
32 
CHAPTER III 
VERIFICATION OF MICROARRAY DATA 
 
 
 During replication DNA methyltransferase 1 (DNMT1) copies the DNA 
methylation pattern from the parent strand onto the daughter strand (Robertson & Jones, 
2000).  Thus, the established methylation pattern is maintained throughout a cell 
lineage.  In contrast, DNMT3a and DNMT3b are responsible for de novo DNA 
methylation (Tsai et al., 2012).  The DNA methyltransferase inhibitor, 5-Azacytidine (5-
Aza), interferes with DNMT1, preventing the re-establishment of DNA methylation 
(Robert et al., 2003).  Therefore, treatment with 5-Aza will result in reduced DNA 
methylation.  The reduction in DNA methylation is dependent partially upon the number 
of cell divisions and consequently the amount of time that a cell is exposed to the drug.  
In the 5-Aza microarray studies of HCT-116 (E-GEOD-57341) and HepG2 (E-GEOD-
5230) available on ArrayExpress, two different periods of time were used for the duration 
of 5-Aza exposure; 72 hours and 96 hours respectively (Dannenberg & Edenberg, 2006; 
Li et al., 2014).  This difference in exposure time could cause a greater relative fold-
change in HepG2 gene expression.  Furthermore, just as length of treatment with 5-Aza 
can cause difference in DNA methylation levels, so to can the concentration (He et al., 
2015; Huichalaf et al., 2014).  In these microarray studies treatment concentrations 
varied by 5 fold; HCT-116 was treated with 0.5 µM 5-Aza whereas HepG2 was treated 
with 2.5 µM.  Verifying the response of the genes to identical treatment conditions of 1 
µM 5-Aza for 72 days, a common treatment for cell lines using the drug, would provide 
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validation of the gene expression data in both cell lines under identical conditions and to 
see if the trend of re-expression was maintained. 
 The goal of the present study was to determine the response of four genes under 
identical treatment conditions, selected based on their unique epigenetic profiles and 
differential response to 5-Aza in the microarrays, both in regards to differing between cell 
lines, and the genes also having very different levels of fold-change from one another.  
Also, the microarray data represents relative fold-change comparing treated to 
untreated.  Examination of the CT values of the qPCR data will allow us to determine if 
the genes are actually in an inactive state and activated by 5-Aza or rather increased in 
expression by 5-Aza.  This has implications regarding the interpretation of the 5-Aza 
microarray data.  To meet this goal, we employed quantitative real-time PCR to 
investigate the relative fold-change of the four genes in comparison to β-actin between 
treated and untreated HepG2 and HCT-116 cells.
Materials and Methods 
Cell Culture and Reagents 
 HCT-116 (obtained from ATCC, Cat. No. CCL-247) was cultured in McCoy’s 5A 
medium, containing 10% FBS, 100 units/mL penicillin, and 100μg/mL streptomycin.  
HepG2 (obtained from ATCC, Cat. No. HB-8065) was cultured in Eagle’s Minimum 
Essential Medium, containing 10% FBS.  Both cell lines were cultured at 37°C in a 
humidified atmosphere with 5% CO2/95% air. 
5-Aza 
 5-Aza was purchased from Acros (Cat. No. 226620500).  Stock solutions of 5-
Aza (220mM) were prepared in 1:1 Acetic Acid:H2O and stored at -20°C.  Stock 
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solutions were further diluted (22mM) in 1:1 Acetic Acid:H2O immediately prior to 
treatments in cell culture experiments. 
Treatment and Collection of Cells 
 HCT-116 and HepG2 were plated in 100mm plates at 7x105 cells.  The next day 
the cells were treated with and without 1μM 5-Aza.  Treatment continued for the next 72 
hours with the medium and 5-Aza being replaced every 24 hours.  At the end of 
treatment the medium was removed and the cells  washed with 5mL of cold 1x PBS.  
Another 5mL of 1x PBS was added and the cells were scraped off the plates and 
transferred to 15mL Falcon tubes.  The cells were pelleted by centrifugation in a clinical 
centrifuge at setting #4.  The supernatant was removed and the pellets quick frozen in 
liquid nitrogen and stored at -80°C. 
RNA Isolation and Evaporation 
 Total RNA was isolated from cell pellets using the Promega SV total RNA 
Isolation System according to manufacturer’s protocol.  Absorbance at 260/280 nm was 
measured for RNA samples using the Synergy 2 multi-mode microplate reader (BioTek) 
and ng/μL was calculated.  Samples with low concentrations were evaporated using a 
Savant SpeedVac Concentrator (SVC100H) and Savant Refrigerated Condensation 
Trap until concentrations were sufficient for cDNA synthesis.  Isolated RNA was stored 
at -80°C until use. 
Conversion to cDNA 
 mRNA was converted to cDNA in 20μL reactions using Maxima’s First Strand 
cDNA synthesis kit and following manufacturer’s instructions for use of 2μg mRNA.  The 
product was then diluted 1:1 using nuclease-free H2O. 
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qPCR of Specific Transcripts 
 Quantitative real-time PCR (qPCR) was carried out in 96-well reaction plates in 
10μL reactions using TaqMan® Gene Expression Master Mix from Applied Biosystems.  
Reactions were run on Applied Biosystems’ StepOnePlus Real time PCR system with 
the following profile: 95°C for 15 seconds and 60°C for 60 seconds for 40 cycles.  
Relative expression of mRNA was calculated by the ∆∆Ct method.  This was done by 
obtaining the ∆Ct value for each sample by subtracting the average Ct value of Actin 
mRNA from the average Ct value of the target gene’s mRNA.  The ∆∆Ct value was then 
obtained by subtracting the treated Ct value from the untreated Ct value.  The mRNA’s 
fold-change was reported using the equation 2^(∆∆Ct) where ∆∆Ct = ((target average 
experimental Ct value – Actin average experimental value) – (target average control Ct 
value – Actin average control value)).  All primers used in qPCR were obtained from 
Applied Biosystems: Actin (Cat. No. Hs00357333_g1), PPDPF (Cat. No. 
Hs00225594_m1), H2AFJ (Cat. No. Hs1674946_s1), MARVELD3 (Cat. No. 
Hs0036935_m1), and MYL9 (Cat. No. Hs00697086_m1).
Results 
 In order to verify that the genes from the microarray studies trended in the same 
direction as our own treatment conditions and to illustrate their validity we treated HCT-
116 and HepG2 cells with 1μM 5-Aza for three days.  These conditions were used in 
order to fall between the two experimental conditions; doubling the concentration seen in 
the HCT-116 microarray yet meeting the same duration, while reducing the 
concentration and duration used in the other. 
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 We hypothesized that treatment of HCT-116 and HepG2 with 5-Aza would 
change the transcript levels of PPDPF, H2AFJ, MARVELD3, and MYL9.  Additionally, 
we suspected that these changes in transcript levels would be due to changes in the 
patterns of epigenetic profiles near the TSS of the genes. 
 Using qPCR we examined the relative fold-change of these four selected targets 
of the microarrays.  These targets came from the list of 32 genes used in the hand 
constructed epigenetic profiles and were chosen based on differential levels of re-
expression.  MYL9 in HepG2 possessed the greatest fold-change relative to actin and 
the largest difference between cell lines.  The gene with the lowest level of reactivation 
of the four genes was PPDPF, with minor difference between HCT-116 and HepG2.  
MARVELD3 showed similar levels of up-regulation in both cell lines, whereas in H2AFJ 
HepG2 was more upregulated than HCT-116 (Fig 6). 
 We were also able to determine the trend of upregulation using the qPCR (Table 
3).  Two of the four genes, MARVELD3, and MYL9 matched the fold-change trends seen 
in the microarray in bothHCT-116 and HepG2.  H2AFJ matched the trends only in 
HepG2.  
 Analysis of the average CT values of the same genes with and without 5-Aza 
treatment revealed that three of the four genes had average CT values of less than 30.  
These values suggest that three of them (PPDPF, MARVELD3, and MYL9) are already 
transcribed in HCT-116 and HepG2.  The level of expression prior to 5-Aza treatment 
does not seem to impact the sensitivity of the gene to 5-Aza treatment.  For example, 
while MYL9 had a CT value in the twenties, suggesting that it was expressed prior to 
treatment with 5-Aza, it responded more so than did H2AFJ which had an average CT 
value of more than 30, and was therefore considered to be expressed only at very low 
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levels.  We observed that while some genes that were “on” seemed to respond better to 
treatment than those that were “off” this trend was not consistent, as seen between 
H2AFJ and PPDPF with an average CT value in the twenties but least amount of 
response in all four genes. 
 When viewing the epigenetic profiles for these genes clear distinctions can be 
made in regards to the patterns of DNA methylation and histone modifications.  In all 
four genes, there was an alteration of the density and level of DNA methylation 
compared to the other genes.  Between cell lines, the greatest difference in DNA 
methylation and histone modifications can be seen in both MYL9 and PPDPF (Fig. 3).  In 
MARVELD3 there is minimal DNA methylation in either cell line within our 1000bp 
window, yet differences between histone modifications exist.
Discussion 
 The goal of this study was to validate the data from the microarrays.  The 
findings from the qPCR analysis were consistent with both our hypotheses that 
treatment with 5-Aza would increase transcript levels and that the increase is based on 
epigenetic profiles.  They also indicate that upregulation was not dependent upon the 
level of transcription prior to drug treatment.  These findings support our model, in that 
the genes which possessed lower levels of DNA methylation near the TSS will show less 
change when treated with 5-Aza.  Genes with a greater number of methylated CpG’s 
near the TSS will show a greater change when treated with 5-Aza. 
 Table 3 is a breakdown of the methylation patterns and histone modifications in 
the 4 genes being analyzed and Table 4 shows the fold-change of these genes after 5-
Aza treatment, analyzed in the microarrays and our qPCR, these changes can also be 
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seen in Fig. 6.  The role of histone modification in relation to the 5-Aza response is more 
complex and less easy to predict.  However, it is known that more active histone marks 
(along with active transcription) preclude DNA methylation and the presence of particular 
histone marks enhance DNA methylation.  We were able to find histone tracks for only 
active histone marks.  It is likely however, that high levels of active histone marks will be 
associated with less activation by 5-Aza.  Of these patterns, the MYL9 gene in HepG2 
fits our model, with 15 sites of methylation and the histone modifications H3K4me1, 
falling in the 250bp regions upstream and downstream of the TSS with H3K4me3 also 
being found in the 250bp upstream region. An additional 12 sites of methylation were 
found outside of the model’s 250bp flanking regions and the continuation of H3K4me1 
across the entire 1000bp region along with the presence of all 3 histone modifications in 
the furthest end of the downstream region added to the epigenetic profile of MYL9.  
While there were more epigenetic modifications within the profile of MYL9 than the 10 to 
15 features suggested by the model, this gene had the greatest response in either cell 
line, with HepG2 possessing a fold-change of 15.52 in our experiment and 28.59 seen in 
the microarray. 
 While this change was seen after 5-Aza treatment in HepG2, it was not seen in 
HCT-116 for MYL9, which only experienced a fold-change of 1.33 in our experiment and 
1.13 in the microarray.  These levels indicate that there was no response to treatment 
with 5-Aza.  HCT-116 did not fit our model, in that it possessed an overall lower level of 
methylation with only 2 sites of methylation in the -250 - -500bp region and the 
H3K4me3 mark downstream of the TSS.  
 Another gene that came close to fitting our model was H2AFJ in HepG2.  In this 
cell line H2AFJ contained 21 sites of methylation and the histone marks H3K4me3 and 
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H3K27ac within the first 250bp flanking each side of the transcription start site.  Further 
upstream and downstream, within our 1000bp window were an additional 3 sites of DNA 
methylation.  This gene slightly exceeded the number of features recommended by our 
model, yet experienced a fold-change of 1.8 and 2.08 in our experiment and the 
microarray respectively.  In H2AFJ, the sites of methylation are primarily found 
downstream, pack relatively closely together.  This likely contributed to the lower level of 
expression than seen in MYL9 (15.52 and 28.59), which had DNA methylation spread 
loosely on both sides of its transcription start site. 
 In HCT-116, H2AFJ did not respond in either our qPCR (0.48) or the microarray 
(1.16).  Rather, there is a decrease in gene transcription in our qPCR after treatment 
with 5-Aza.  The lack of response measured in the microarray matches our prediction 
based on the model, as H2AFJ in HCT-116 exceeded the recommended number of 
features, possessing 28 locations of DNA methylation within the first 250bp, upstream 
and downstream along with H3K4me3 and H3K27ac, with the majority (23 sites) of the 
methylation being located upstream of the TSS.  A total of 3 other locations were found 
to have DNA methylation in both the -/+500bp regions with continued H3K4me3 and 
H3K27ac marks. 
 PPDPF failed to meet the criteria of our model in both HCT-116 and HepG2 and 
possessed a fold-change of only 0.37 and 1.11 for our qPCR and the microarray in HCT-
116 and 0.67 in our experiment and 1.75 from the microarrays for HepG2.  In HCT-116 
there was no DNA methylation and only 2 histone marks, H3K4me3 and H3K27ac.  
HepG2 possessed DNA methylation downstream only, with 8 being found in the first 
250bp and an additional 21 from 251bp – 500bp.  It also contained the histone mark 
H3K4me3 throughout the entirety of the 1000bp window.  The levels of fold-change 
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measured in PPDPF via the microarray, illustrate a lack of response when there is little 
to no methylation, while our own results suggest that there was a repression of 
transcription upon 5-Aza treatment. 
 MARVLED3 is another example of a gene that does not fit the model, as it 
contains no DNA methylation in either HCT-116 or HepG2.  In HepG2 H3K4me3 is 
found throughout the 1000bp region, while in HCT-116 it is seen only from TSS to 500bp 
downstream.  It is not surprising that our qPCR found MARVELD3 to have no change as 
indicated by the 1.08 and 1.23 levels of fold-change in HCT116 and HepG2 respectively.  
However, the microarray found different responses after treatment after 5-Aza, with fold-
change levels 4.21 in HCT-116 and 2.36 in HepG2, indicating that the gene had 
responded and done so more in HCT-116 than in HepG2. 
 Overall, we found that 2 of the 4 verified genes in HepG2 fit our model’s 
requirements for reactivation, while none fit the requirements in HCT-116.  Those genes 
that did not fit the requirements met our prediction that there would be little response in a 
gene that did not fit the requirements based on the model.  Additionally, we were able to 
verify through qPCR that 3 of the 4 genes, MYL9, H2AFJ, and PPDPF, matched the 
fold-change trends seen in the microarray.  One gene did not match the trend of 
expression between our experiment and the data gathered from the microarray, 
MARVELD3, which possessed a fold-change of 1.08 in HCT-116 and 1.23 in HepG2 as 
seen in our qPCR.  In the microarrays MARVELD3 showed a fold-change of 4.21 and 
2.36 for HCT-116 and HepG2 respectively.   
 An investigation of the individual CT values of MARVELD3 illustrates that there 
was no reading that skewed the data, as even in the most extreme case cycle times 
differed by less than 0.7.  The inversion of response between HCT-116 and HepG2 seen 
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in H2AFJ could likely be due to the fact that the CT values were near the thirties, where 
there is a greater margin of error.  When low levels of transcript are present during the 
initial rounds of the polymerase chain reaction, lack of replication of even a single strand 
during the first reaction can result in a reduction of the transcripts at the 30th cycle by 
more than a billion copies.  Alternatively, there may have been an indirect effect on this 
gene or a gene enhancer outside of our considered region. 
 Another issue that must be considered is indirect effects of the 5-Aza.  It is 
possible that the change in expression of some of these genes, particularly MARVELD3 
with no methylated CpGs, is due to secondary effects.  That is, another gene is being 
activated and affecting MARVELD3, either as an enhancer or transcription factor.  
Similar results with another gene have been seen in other studies and confirmed that 
indirect mechanisms were affecting the upregulation of genes after 5-Aza treatment 
(Angst et al., 2011).  It is also possibly affecting the mRNA stability.  This is important as 
our basic assumption for the entire project rests on the idea that most changes in gene 
expression are due to 5-Aza treatment and the direct effects on a particular gene.  Of the 
four genes we selected, it is most likely that MYL9 is directly affected by 5-Aza.  This 
conclusion is based on the finding that its epigenetic profile of methylation in HepG2 
most closely matches our model and it’s total of 27 sites of DNA methylation are spread 
throughout the 1000bp region.  Had this been an indirect effect, it is likely that we would 
have seen a response in HCT-116 similar to that of HepG2.  This was not observed. 
 As an alternative to the microarray, RNA-seq would have been a more effective 
method as it would have been able to more accurately determine the level of gene 
expression before and after treatment.  Our method, while useful in determining 
reactivation or upregulation of a gene, does so based on a comparison between the 
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level of fluorescence of a given transcript and that of the transcript for β-Actin.  Using 
RNA-seq would provide a more accurate quantification of lowly expressed genes, while 
simultaneously giving an exact level of gene transcription.  The use of RNA-seq would 
allow for identification of “on” / ”off” genes while potentially avoiding the issues seen with 
MARVLED3.  
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Table 3. Count of DNA Methylation and Histone Modifications of Four Verified Genes.  A count of the 
DNA methylation and list of the histone modifications present in each 250bp region of the 1000bp window of 
investigation for the four verified genes (PPDPF, H2AFJ, MYL9, and MARVELD3). 
 
 
   
44 
Table 4. qPCR VS Microarray Results for 4 Verified Genes.  Relative fold change as determined by 
qPCR in the four verified genes (PPDPF, H2AFJ, MARVELD3, and MYL9) compared to fold change seen in 
the microarrays.  Difference (experimental/microarrays) is the difference between the two cell lines for a 
given gene. 
 
 
  
45 
 
 
Figure 6. Graph of Relative Fold-Change in Verified Genes.  Reactivation of verified genes: PPDPF, 
H2AFJ, MARVELD3, and MYL9 after treatment with 5-Azacytidine in HCT-116 and HepG2.
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CHAPTER IV 
PREDICTING THE RE-EXPRESSION OF NOVEL GENES USING EPIGENETIC 
PROFILES 
 
 
 The major goal of this study was to determine if the model that we derived in 
Chapter II can be applied to the re-expression of a novel gene by treatment of 5-Aza.  
That is, will the epigenetic profile of the novel gene be predictive of its expression.  For 
this experiment we used the gene WNT5A.  
 WNT5A is a secreted protein ligand that is misregulated in multiple forms of 
cancer and plays a role in migration, adhesion, differentiation, proliferation, and 
apoptosis(Kikuchi et al., 2012).  In some cancers, WNT5A is upregulated and 
recognized as an oncogene, whereas in others it is downregulated and implicated as a 
tumor suppressor (Hung et al., 2014; Ying et al., 2008).  Further studies have found that 
this gene possesses two isoforms (Fig. 7).  There is limited evidence that these isoforms 
are functionally distinct (Bauer, er al.).  Importantly, for this study the isoforms are 
derived from unique mRNA’s, transcribed from unique promoters.  The TSS of these two 
promoters lie 6,244 base pairs away from one another and therefore represent adequate 
distance that does not overlap in the use of our epigenetic profiling.  In this lab we had 
previously investigated the methylation status and transcription of WNT5A in multiple cell 
lines.  WNT5A isoform A and B promoters were found to be inactive in HCT-116 cells. 
(Vaidya et al., 2016, and unpublished). A second goal of this study was to determine if 
WNT5A could be further re-activated using a combination of the DNA methyltransferase 
inhibitor, 5-Azacytidine, and the histone deacetylase inhibitor, SAHA  also known as 
Vorinostat or suberoylanilide.Hydroxamic.  This drug is a histone deacetylase inhibitor 
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that inhibits all class I and class II HDACs (Marks, 2007) that has been approved by the 
FDA for use in cutaneous T-cell lymphoma (W. S. Xu et al., 2007).  SAHA binds to the 
catalytic region of these HDACs, preventing the removal of the acetyl group from 
histones (Yoon & Eom, 2016).  It has been shown in previous studies that combinations 
of HDACi and DNMTi can have a synergistic effect (Chen et al., 2012; Leclercq et al., 
2011). 
 To achieve our goals we used ENCODE to examine the pattern of DNA 
methylation and histone modifications surrounding the WNT5A promoter A and promoter 
B.  Then HCT-116 cells were treated with combinations of the DNA demethylating agent, 
5-Aza and histone deacetylase inhibitor, SAHA.  The derived pattern of DNA methylation 
and histone modifications were then compared to the expression pattern.
Materials and Methods 
Cell Culture and Reagents 
 HCT-116 (obtained from ATCC, Cat. No. CCL-247) was cultured in McCoy’s 5A 
medium, containing 10% FBS, 100 units/mL penicillin, and 100μg/mL streptomycin.  
HepG2 (obtained from ATCC, Cat. No. HB-8065) was cultured in Mem-C medium, 
containing 10% FBS.  Both cell lines were cultured at 37°C in a humidified atmosphere 
with 5% CO2/95% air. 
Treatment with 5-Aza and SAHA 
 5-Aza was purchased from Acros (Cat. No. 226620500).  Stock solutions of 5-
Aza (220mMol/L) were prepared in 1:1 Acetic Acid:H2O and stored at -20°C.  Stock 
solutions were further diluted (22mMol/L) in 1:1 Acetic Acid:H2O immediately prior to 
treatments in cell culture experiments.  Treatment with 5-Aza (either 1μM or 5μM) took 
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place over 72 hours with medium and 5-Aza being replaced every 24 hours.  SAHA was 
obtained from TSZ Chem (Cat. No. RV005) and stored at -20°C.  Solutions of SAHA 
(10mMol/L) were prepared in DMSO immediately prior to use in cell culture experiments.  
Treatment with SAHA (either 1μM or 5μM) took place over 24 hours.  Cells were 
collected in 5mL PBS after treatment, supernatant was removed, cell pellets were frozen 
and stored at –80°C. 
RNA Isolation and Evaporation 
 Total RNA was isolated from both cell lines using Promega’s SV total RNA 
isolation system according to manufacturer’s protocol.  Absorbance at 260/280 nm was 
measured for RNA samples using the Synergy 2 multi-mode microplate reader (BioTek) 
and ng/μL was calculated.  Samples with low concentrations were evaporated using a 
Savant SpeedVac Concentrator (SVC100H) and Savant Refrigerated Condensation 
Trap until concentrations were sufficient for cDNA synthesis.  Isolated RNA was stored 
at -80°C until use. 
Conversion to cDNA 
 mRNA was converted to cDNA in 20μL reactions using Maxima’s First Strand 
cDNA synthesis kit and following manufacturer’s instructions for use of 2μg mRNA.  The 
product was then diluted 1:1 using nuclease-free H2O. 
Quantification of mRNA, qPCR 
 Quantitative real-time PCR was carried out in 96-well reaction plates in 10μL 
reactions using TaqMan® Gene Expression Master Mix from Applied Biosystems.  
Reactions were run on Applied Biosystems’ StepOnePlus Real time PCR system with 
the following profile: 95°C for 20 seconds followed by 40 cycles of 95°C for 3 seconds 
and 60°C for 30 seconds.  Relative expression of mRNA was calculated by the ∆∆Ct 
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method.  This was done by obtaining the ∆Ct value for each sample by subtracting the 
average Ct value of Actin mRNA from the average Ct value of the target gene’s mRNA.  
The ∆∆Ct value was then obtained by subtracting the treated Ct value from the 
untreated Ct value.  The mRNA’s fold-change was reported using the equation 2^(∆∆Ct).  
All primers used in qPCR were obtained from Applied Biosystems: Actin (Cat. No. 
Hs00357333_g1), WNT5A isoform A (Cat. No. AID1VPA) and WNT5A isoform B (Cat. 
No. AIFATVI). 
Construction of “epigenetic profiles” 
 “Epigenetic profiles,” defined as 1000bp regions centered at the transcription 
start site and consisting of DNA methylation and histone mark scores and abundance, 
were constructed in two different manners; initially by hand for a group of 32 selected 
genes and later by using a mixture of GALAXY, ENCODE, and Excel.  
 Hand construction of the epigenetic profiles was performed using ENCODE to 
explore the methylation and histone modification tracks of 32 genes selected from the 
microarray studies based on differential re-expression of any given gene between cell 
lines.  Each track was examined in windows of 50 base pairs each starting at the 
transcription start site and extending 500 base pairs in each direction.  Methylation data 
was collected for HCT-116 and HepG2 by analyzing two RRBS tracks for HCT-116 and 
two RRBS tracks for HepG2; these numbers were averaged together for the tracks of 
each cell line and recorded.  Additionally, two 450K tracks for HCT-116 and one 450K 
track for HepG2 were collected and recorded.  When more than one track was available 
the scores for 450K were averaged in the same manner as RRBS.  When analyzing 
histone modifications, we selected those which were shared between the two cell lines:  
H3K4me1, H3K4me3, and H3K27ac tracks (all which are associated with active 
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promoters).  Two tracks were used for analysis of HCT-116 H3K4me3 (Peaks 1 & 2), 
while 3 were used to analyze the same modification in HepG2 (Peaks 1, 2, & 
ENCODE/Broad).  In the event that a peak was detected that stretched outside of the 50 
base pair window, the score was carried over into all 50bp windows that it was located 
in, so long as it accounted for at least 25bp of that window.  No scores were given for 
anything further than 500bp up/downstream.  If more than one peak was present in a 
single track set, the two scores were averaged if they were the same length, so long as 
both accounted for at least 25bp of the given window and they were the same length, if 
not the shorter band’s score was taken since it is considered more accurate by 
ENCODEs standards.  For all histone tracks and the 450K track, numbers ranged from 0 
– 1000; the RRBS track ranged from 0 – 100.  These numbers indicated the RRBS track 
indicated the percentage of reads that showed methylation at a given CpG, whereas the 
450K track scored based on the microarrays beta values, multiplied by 1000.  Histone 
tracks were scored based on the signal value, indicating the average enrichment for the 
region.  When available, multiple tracks of a given epigenetic mark are used as a form of 
biological replicates.
Results 
 We examined the bioinformatics information available on ENCODE to construct 
the epigenetic profiles of WNT5A isoform A and B promoters.  As before, we used a 
1000bp window of 500bp upstream and downstream of the TSS of WNT5A promoters 
(Fig. 8).  We found that HCT-116, WNT5A promoter A, contained 12 sites of DNA 
methylation.  Eight of these sites are located from +500 to +251bp, 2 from +250 to the 
TSS and 2 more from the TSS to +250bp downstream.  These scores come from a 
combination of both the 450K and RRBS tracks.  Generally, these sites were found 
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downstream of TSS, located in Exon1 (Fig11A), while only two of them were found 
upstream.  Four sites of methylation occurred spread out over 250bp upstream and 
downstream of the TSS.  The eight remaining sites were found further downstream.  The 
same sites were analyzed in HepG2 for promoter A, yet only two sites were found by the 
450K microarray to have partial methylation scores; all other sites in the region were 
found to have no methylation.  In both HCT-116 and HepG2, WNT5A promoter B, 
contained 4 identical sites of DNA methylation (Fig. 8, Fig. 9B).  These sites were 
located in the TSS to +250bp region as identified by 450K. 
 Both promoter A and promoter B lacked any histone modifications for HCT-116 
and HepG2 within our window.  Expansion of our window revealed a single H3K4me1 
histone mark over 4000bp upstream of the TSS for promoter B and over 2000bp 
downstream of the TSS for promoter A, separating the two.  This suggests that the two 
promoters are heavily regulated by DNA methylation and transcription factors. 
 Bisulfite sequence analysis had been completed in the lab on a portion of 
promoter B including 4 CpGs.  All four of these sites were found to be methylated (Fig. 
9B).  These sites fall within the 1000bp window of our WNT5A promoter B epigenetic 
profile and were not found to be methylated in the ENCODE tracks (Fig. 8).  Based on 
these findings it would be predicted that the high-throughput sequencing methods 
utilized to generate the ENCODE data do not pick up every site of methylation. 
 From our analysis of the epigenetic profiles of the two WNT5A promoters in HCT-
116 and HepG2 we expected HCT-116 promoter A to have the greatest response to 5-
Aza.  These expectations come from the fact that it more closely resembles our model 
generated after PCA and elastic net regression due to its 12 sites of DNA methylation 
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within the entire 1000bp region, 4 of which fall within the 250bp flanking regions of the 
transcription start site.  To investigate this, we treated HCT-116 and HepG2 cells with 
1µM 5-Aza for 72 hours and performed qPCR using custom, promoter specific probes.  
We found that WNT5A promoter A in HCT-116 became re-expressed to a higher degree 
than that HepG2 or isoform B in either HCT-116 or HepG2.  Furthermore, WNT5A 
promoter B experienced the same level of relative fold-change in both HCT-116 and 
HepG2, while promoter A in HepG2 was found to be re-expressed more than promoter 
B, but less than that of promoter A in HCT-116. 
 The epigenetic profiles of the WNT5A promoters A and B regions that were 
derived from ENCODE did not include any histone modifications, active or repressive.  
Taking this finding into account and based on our model, we would predict that drugs 
affecting histone acetylation or methylation would have an effect on promoter A and B 
expression. 
 To test this prediction we treated HCT-116 with1µM or 5µM 5-Aza and/or SAHA 
for 72 hours with 5-Aza and applying SAHA for the last 24 hours.  We found that WNT5A 
promoter A was reactivated with all treatments.  Used alone, 1µM 5-Aza increased 
expression 3.68 fold, and 5µM would cause a fold-change of 6.17.  Using SAHA alone 
increased the fold-change to 5.35 at 1µM and to 8.15 at 5µM.  When used in 
combination the effect was even greater, showing a fold change of 26.24 (1µM 5-Aza, 
1µM SAHA), 79.03 (1µM 5-Aza, 5µM SAHA), and 143.74 (5µM 5-Aza, 1µM SAHA).  
Promoter B was found to be less responsive to treatment, showing a fold change of 1.43 
with 1µM 5-Aza, and 0.39 when treated with 5µM 5-Aza.  SAHA caused a fold-change of 
0.64 at 1µM and 1.86 at 5µM.  When used in combination, the fold-changes of 38.68 
(1µM 5-Aza, 1µM SAHA), 36.95 (1µM 5-Aza, 5µM SAHA), and 43.15 (5µM 5-Aza, 1µM 
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SAHA) were measured.  Again, promoter A was more responsive to treatment than 
promoter B.
Discussion 
 The epigenetic profiles of HCT-116 and HepG2, as determined by the ENCODE 
analysis was found to be identical for WNT5A promoter B.  Each cell line showed only 4 
sites of methylation at the same location and both lacked any form of histone 
modification. The prediction, based on our model was that these cell lines would display 
a low level of response when exposed to 5-Aza treatment.  The results show that 
promoter B is unresponsive to 5-Aza in both HCT-116 and HepG2.  The epigenetic 
profiles of promoter A for HCT-116 and HepG2 were distinctly different with HCT-116 
having 12 methylated CpGs and HepG2 having only 2.  This means that HCT-116 would 
be more responsive to treatment with 5-Aza because of the impact methylation has on 
transcription.  Our results support this prediction, as promoter A in HCT-116 is activated 
nearly 6-fold by 5-Aza.  However, in spite of only the two methylation sites, which are 
located in the +500 interval, promoter A is activated 3-fold in HepG2.  Although the 
activation is less then in HCT-116, it is responsive to 5-Aza, unlike promoter B in HCT-
116.  Overall, these results, partially support the model that more DNA methylation is 
related to the responsiveness to 5-Aza. 
 Looking at epigenetic profiles in small windows such as our 1000bp region with 
50bp bins can provide unique insights that might otherwise not be noticeable.  Promoter 
B shows identical methylated CpG sites in both HepG2 and HCT-116.  These 4 
methylated sites and lack of histone modifications fall well below the model’s number but 
allow us to look closer at the fold changes between cell lines with matching epigenetic 
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profiles.  When treated with 1μM 5-Aza both HCT-116 and HepG2 promoter B was 
unaffected and showed no change.  With identical epigenetic profiles and matching 
treatment conditions, the identical response of promoter B in both cell lines matches 
expectations. 
 Unpublished data from our lab illustrates the limits of bioinformatics data.  We 
found 4 additional sites of methylation in promoter B that had not been assayed by the 
RRBS or 450K tracks of HCT-116 used in ENCODE.  It is likely then, that many more 
methylation sites were missed in WNT5A promoter A and promoter B along with other 
genes of both of these cell lines.  While there may be other sites of methylation, we have 
based our model on information that is obtainable through bioinformatics and databases 
such as ENCODE and therefore, feel that the model is still applicable. 
 In comparison to the four genes we verified (PPDPF, H2AFJ, MARVELD3, and 
MYL9), MYL9 showed the highest level of fold-change in both cell lines; 15.51 in HepG2 
and 1.33 in HCT-116.  In comparison, WNT5A promoter A showed a fold-change of 6.16 
in HCT-116 and 3.9 in HepG2.  Based on our model, it would be predicted that the 
epigenetic profiles of MYL9 and WNT5A Promoter A would include methylated sites and 
that MYL9 would be more highly methylated in HepG2 and WNT5A would be more 
highly methylated in HCT-116.  In fact, MYL9 was found to have 27 methylation sites in 
the epigenetic profile for HepG2 and only 2 for HCT-116.  In contrast, WNT5A promoter 
A was found to have 12 methylation sites in HCT-116 and only 2 in HepG2.  Thus, the 
epigenetic profiles of the MYL9 gene and novel gene WNT5A promoter A fit the 
prediction.  Other factors likely contribute to the unique epigenetic profiles of each gene. 
 We predicted that SAHA, a histone deacetylase inhibitor would have an effect on 
promoters A and B expression.  This prediction is based on the findings that no histone 
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acetylation was found surrounding the WNT5A promoters A or B through the H3K27ac 
track on ENCODE and therefore may be undergoing histone deacetylation.  We saw a 
response to treatment with SAHA alone and in combination with 5-Aza at promoter A, 
whereas promoter B displayed a fold-increase only when SAHA was used in 
combination with 5-Aza.  Treatment with both 1µM and 5µM SAHA, alone, increased 
expression from promoter A in the range of that seen with 5-Aza treatment.  When 
SAHA was combined with 5-Aza, expression was increased even higher to 
approximately 10 to 20 times higher than either compound alone.  These finding suggest 
that, indeed, histone modifications plays some role in the epigenetic state of promoter A 
in HCT-116 cells. 
 In contrast to promoter A, promoter B is less responsive to SAHA; only in 
combination with 5-Aza was there a substantial increase in promoter activity (38-42 fold).  
This finding illustrates that both promoters are responsive to SAHA.  This suggests that 
normally this region is being deacetylated by HDACs.  One approach to clarify this issue 
would be to perform ChIP analysis on both promoters A and B for a H3K27ac. 
 In summary, we used the two distinct promoters of WNT5A as “novel genes” to 
investigate if the pattern of re-activation of these promoters by the epigenetic drugs 5-
Aza was found to be higher in cell lines with greater methylation as a means to test our 
model from Chapter II.  WNT5A promoter A and another selected gene MYL9 were 
found to be somewhat consistent with the model.  Surprisingly, promoter B was 
unaffected by 5-Aza but this lack of response was identical in both HCT-116 and HepG2, 
which have identical epigenetic profiles.  SAHA was found to have a strong positive 
effect on expression, especially in combination with 5-Aza.  This is what was expected, 
as the epigenetic profiles were void of histone marks.  
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Figure 7. WNT5A Alternative Isoforms.  WNT5A isoforms.  (A) Genomic structure of the WNT5A gene.  
Arrow indicates transcription start sites of promoter A and Promoter B.  (B) Primary transcripts for Promoter 
A (top) and Promoter B (bottom).  Red boxes indicate 1000bp region of investigation centered at the TSS.  
Exons represented by filled boxes and introns, illustrated by lines to the left of the TSS display their specific 
size in parentheses.  
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Figure 8. ENCODE Snapshot of WNT5A Promoter A and Promoter B.  ENCODE snapshot showing 
500bp flanking regions of the WNT5A promoter A transcription start site (top) and WNT5A promoter B 
transcription start site (bottom) methylation and histone modifications.  DNA methylation in RRBS tracks is 
shown in either red (100% methylated), yellow (50% methylated), or green (0% methylated).  
Representation of DNA methylation as found via 450K array is shown in either orange (methylated), purple 
(partially methylated), or blue (un methylated).  The red bar in the center is helps to identify location, with the 
center being at the transcription start site and a 250bp region blocked off on each side (where then thin red 
line ends); these regions are divided in half representing (2) 125bp regions.  Gene is on the negative strand.
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Figure 9. Visualization of the WNT5A Methylation Sites in the Sequence.  The sequence of WNT5A at 
Promoter A (A) and Promoter B (B) 500bp upstream and downstream from the transcription start site 
indicated by blue arrow.  Exons are illustrated in upper case, introns in lower case.  All CpGs within the 
sequence have been boxed in.  Shaded CpGs represent sites where ENCODE found methylation at ≥50% 
(RRBS) or at least partially methylated (450K) in HCT-116 and HepG2.  The blue, boxed in area represents 
the first exon of each promoter.  
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Table 5. Count of DNA Methylation and Histone Modifications of WNT5A Promoters A and B. A count 
of the DNA methylation and list of the histone modifications present in each 250bp region of the 1000bp 
window of investigation for the two novel genes (WNT5A Promoter A and WNT5A Promoter B). 
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Table 6. qPCR VS Microarray Results for WNT5A Promoters A and B. Relative fold change as 
determined by qPCR in the two “novel genes” (WNT5A promoter A and promoter B.  Difference 
(experimental) is the difference between the two cell lines for a given gene. 
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Figure 10. Graph of Relative Fold-Change in WNT5A Promoters A and B.  Reactivation of novel genes 
WNT5A promoter A and promoter B after treatment with 5-Azacytidine in HCT-116 and HepG2. 
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Figure 11. Graph of Relative Fold-Change in WNT5A Promoters A and B Using Combinatorial 
Treatment. Relative fold-change of WNT5A promoter A and B transcript level expression after treatment 
with 5-Azacytidine (5-Aza) and SAHA. HCT-116 cells were treated with the indicated amounts of 5-Aza and 
SAHA as described in Materials and Methods.  The levels of promoter A and promoter B transcripts 
determined by qPCR and relative levels determined based on actin transcripts. Error bars represent 
standard deviation.
PromoterA PromoterB
1µmol/L  5‐Aza 3.68 1.43
5µmol/L  5‐Aza 6.17 0.39
1µmol/L  SAHA 5.35 0.64
5µmol/L  SAHA 8.15 1.86
5‐Aza & SAHA: 1:1 26.24 38.68
5‐Aza & SAHA: 1:5 79.03 36.95
5‐Aza & SAHA: 5:1 143.74 43.15
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